LCZ696

  • Novartis
    August 31, 2014  

    An experimental heart drug developed by the Swiss pharmaceutical company Novartis shows promising results. The new drug, currently referred to as “L C Z 696” may change the course of treatment and prolong the lives of patients suffering from heart failure. For some insight, Dr. Clyde Yancy, Professor of Medicine and Chief of Cardiology at Northwestern University joins Hari Sreenivasan via Skype from Windham, New Hampshire. Continue reading